Amoy Diagnostics Co., Ltd. (300685.SZ)
CNY 21.0
(-0.43%)
CNY 21.0
(-0.43%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -92.73 Million CNY | 78.97% |
| 2022 | -441.04 Million CNY | -11.15% |
| 2021 | -396.81 Million CNY | -36.8% |
| 2020 | -290.06 Million CNY | 41.21% |
| 2019 | -493.39 Million CNY | -164.5% |
| 2018 | -186.53 Million CNY | -12.48% |
| 2017 | -165.84 Million CNY | -129.43% |
| 2016 | -72.28 Million CNY | -18.2% |
| 2015 | -61.15 Million CNY | -599.27% |
| 2014 | 12.24 Million CNY | 13.28% |
| 2013 | 10.81 Million CNY | 174.77% |
| 2012 | -14.46 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -731.83 Million CNY | -5.1% |
| 2024 Q2 | -696.33 Million CNY | -6.94% |
| 2024 Q1 | -651.15 Million CNY | -602.2% |
| 2023 Q3 | -475.25 Million CNY | 3.18% |
| 2023 Q4 | -92.73 Million CNY | 80.49% |
| 2023 FY | -92.73 Million CNY | 78.97% |
| 2023 Q1 | -462.34 Million CNY | -4.83% |
| 2023 Q2 | -490.87 Million CNY | -6.17% |
| 2022 Q4 | -441.04 Million CNY | -13.15% |
| 2022 Q1 | -435.78 Million CNY | -9.82% |
| 2022 Q2 | -420.55 Million CNY | 3.49% |
| 2022 FY | -441.04 Million CNY | -11.15% |
| 2022 Q3 | -389.78 Million CNY | 7.32% |
| 2021 Q3 | -343.55 Million CNY | 11.62% |
| 2021 FY | -396.81 Million CNY | -36.8% |
| 2021 Q1 | -376.23 Million CNY | -4.06% |
| 2021 Q2 | -388.71 Million CNY | -3.32% |
| 2021 Q4 | -396.81 Million CNY | -15.5% |
| 2020 Q3 | -422.95 Million CNY | -33.16% |
| 2020 FY | -290.06 Million CNY | 41.21% |
| 2020 Q2 | -317.63 Million CNY | 15.5% |
| 2020 Q1 | -375.87 Million CNY | 23.82% |
| 2020 Q4 | -361.56 Million CNY | 14.52% |
| 2019 Q2 | -252.86 Million CNY | -4.91% |
| 2019 Q3 | -261.96 Million CNY | -3.6% |
| 2019 Q1 | -241.02 Million CNY | -29.21% |
| 2019 Q4 | -493.39 Million CNY | -88.34% |
| 2019 FY | -493.39 Million CNY | -164.5% |
| 2018 Q1 | -170.46 Million CNY | -2.78% |
| 2018 FY | -186.53 Million CNY | -12.48% |
| 2018 Q4 | -186.53 Million CNY | -31.11% |
| 2018 Q2 | -183.9 Million CNY | -7.88% |
| 2018 Q3 | -142.27 Million CNY | 22.64% |
| 2017 Q1 | 82.28 Million CNY | 213.83% |
| 2017 Q3 | -214.44 Million CNY | -131.76% |
| 2017 Q4 | -165.84 Million CNY | 22.66% |
| 2017 FY | -165.84 Million CNY | -129.43% |
| 2017 Q2 | -92.52 Million CNY | -212.45% |
| 2016 FY | -72.28 Million CNY | -18.2% |
| 2016 Q1 | 71.85 Million CNY | 217.5% |
| 2016 Q4 | -72.28 Million CNY | 0.0% |
| 2015 Q4 | -61.15 Million CNY | 0.0% |
| 2015 FY | -61.15 Million CNY | -599.27% |
| 2015 Q2 | -50.03 Million CNY | -1.21% |
| 2015 Q1 | -49.43 Million CNY | 0.0% |
| 2014 FY | 12.24 Million CNY | 13.28% |
| 2013 FY | 10.81 Million CNY | 174.77% |
| 2012 FY | -14.46 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.31 Billion CNY | 107.034% |
| Hangzhou Tigermed Consulting Co., Ltd. | -4.06 Billion CNY | 97.717% |
| Dirui Industrial Co.,Ltd. | -131.62 Million CNY | 29.547% |
| Beijing Strong Biotechnologies, Inc. | 411.59 Million CNY | 122.53% |
| Medicalsystem Biotechnology Co., Ltd. | -850.71 Million CNY | 89.1% |
| Maccura Biotechnology Co.Ltd | -170.79 Million CNY | 45.705% |
| Guangzhou Wondfo Biotech Co.,Ltd | -240.75 Million CNY | 61.483% |
| Guangdong Hybribio Biotech Co.,Ltd. | -708.27 Million CNY | 86.908% |
| BGI Genomics Co., Ltd. | -3.63 Billion CNY | 97.45% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -486.57 Million CNY | 80.942% |